TRIM26 and metabolic syndrome: As expected, rabbits with LV-Trim26 injection via liver portal vein presented downregulated dyslipidemia, hepatic steatosis, and hepatic injury compared to those in LV-Control groups after 8 weeks of HFHC diet treatment, as confirmed by liver lipid contents detection, serum glucose and insulin assay, H&E staining, oil red O staining, and serum contents of liver function indicators (P < 0.01 by 2 tailed t test; Fig. 8j–m).